Which statement correctly describes UDCA use in cholestatic liver diseases?

Prepare for Liver Disease and Tumors Test with tailored flashcards and questions. Get detailed explanations and improve your knowledge. Ace the medical student exam!

Multiple Choice

Which statement correctly describes UDCA use in cholestatic liver diseases?

UDCA is a hydrophilic bile acid that helps protect the bile ducts and improve bile flow, while reducing the toxic effects of more harmful bile acids. In primary biliary cholangitis it is the standard first‑line therapy, and it improves biochemical markers and can improve long‑term outcomes. In primary sclerosing cholangitis it is also commonly used and can improve liver enzymes and may extend transplant‑free survival in some patients, though it is not a cure. It is not beneficial in alcoholic liver disease, and PSC is not cured by UDCA. Therefore, UDCA’s use in both primary biliary cholangitis and primary sclerosing cholangitis best reflects its role.

UDCA is a hydrophilic bile acid that helps protect the bile ducts and improve bile flow, while reducing the toxic effects of more harmful bile acids. In primary biliary cholangitis it is the standard first‑line therapy, and it improves biochemical markers and can improve long‑term outcomes. In primary sclerosing cholangitis it is also commonly used and can improve liver enzymes and may extend transplant‑free survival in some patients, though it is not a cure. It is not beneficial in alcoholic liver disease, and PSC is not cured by UDCA. Therefore, UDCA’s use in both primary biliary cholangitis and primary sclerosing cholangitis best reflects its role.

More practice questions